Phenomenex Adds New Lux® Amylose-1 Chiral Stationary Phase
Product News Sep 01, 2015
Phenomenex Inc. has announced the addition of an Amylose-1 chiral stationary phase to its high-efficiency Lux polysaccharide chiral column line. The affordable Amylose-1 adds valuable enantioselectivity to the Lux column family with the chiral selector amylose tris (3,5-dimethylphenylcarbamate), and is a guaranteed alternative to other phases with the same chiral selector. Offered in 5µm particles, the new media is available in analytical columns and Phenomenex-patented Axia™ preparative column hardware, both of which are stable in normal phase, reversed phase, polar organic and SFC conditions.
The Phenomenex Axia preparative format delivers longer column lifetime, higher efficiencies, improved performance and high reproducibility, compared with conventionally packed columns for lab-scale preparative HPLC and SFC chromatography.
The expanded Phenomenex Lux chiral column line of six amylose and cellulose chiral selectors comprises an affordable and complementary kit for chiral separations, featuring high efficiency, excellent loading capacity and pressure stability up to 300 bar in a wide range of conditions.
Ideal applications for Lux columns include drug enantiomers from the pharmaceutical sector, chiral pesticide analysis in agrochemical settings, flavor analysis and production from the food industry, fragrance isolation and commercialization in cosmetics and a range of other chiral-chemical raw materials such as intermediates and finished goods.
“The high enantiorecognition and complementary phases of the Lux column line simplify chiral separations at affordable costs and are delivered with an unparalleled product quality guarantee,” comments Simon Lomas, strategic marketing manager for Phenomenex. “The introduction of the highly anticipated Lux Amylose-1 further ensures customer success for even the most challenging chiral HPLC or SFC separations.”
To complement its comprehensive Lux chiral column line, Phenomenex offers free chiral screening services with greater than 90 percent success rates from its PhenoLogix application development group, along with over 2,000 chiral applications online that are easily searchable by compound structure or name.